How long does it take Ilumya to work?

Drugs.com

Official answer

by Drugs.com

It takes approximately 12 weeks for Ilumya (tildrakizumab) to start working with nearly 60% of people experiencing a 75% reduction in the severity of their psoriasis within that time; however, it may take over a year for the full benefits to be seen.

Research has shown that after 12 weeks:

  • 55% to 58% of people administered Ilumya had cleared or minimal disease according to their PGA (physicians global assessment) score compared to 4% to 7% of those administered placebo
  • 61% to 64% had experienced a 75% reduction in their disease as defined by their PASI score
  • 35% to 39% had experienced a 90% reduction in their disease as defined by their PASI score
  • 12% to 14% had experienced a 100% reduction in their disease as defined by their PASI score.

    • Longer-term studies have indicated the percentage of people experiencing benefit increases with continued treatment.

  • After 28 weeks of treatment, 74% of people administered Ilumya had experienced a 75% reduction in their disease as defined by their PASI score
  • After 64 weeks of treatment, 84% of people administered Ilumya had experienced a 75% reduction in their disease as defined by their PASI score.

    • Some people who previously been assigned Ilumya in the trial were then given a placebo. It took an average of 20 weeks for the benefits of Ilumya to be lost once it had been discontinued.

    Related medical questions

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords